HCC

Lenvatinib (Lenvima) has been approved by the European Commission as a first-line treatment for adults with advanced or unresectable hepatocellular carcinoma, based on data from the phase III REFLECT trial.

Lenvatinib (Lenvima) has been granted approval by the FDA as a first-line treatment for patients with unresectable hepatocellular carcinoma, based on data from the phase III REFLECT trial.

Compared with sorafenib (Nexavar) alone, sorafenib in combination with selective internal radiation therapy did not provide a significant survival improvement for patients with advanced hepatocellular carcinoma, according to results from the palliative cohort of the SORAMIC trial presented at the 2018 World Congress on Gastrointestinal Cancer in Barcelona, Spain. However, overall survival improvements were seen with the combination in select subgroup analyses.

The FDA issued several approvals in July, including in colorectal cancer, breast cancer, prostate cancer, and acute myeloid leukemia. Here’s a look back on the FDA happenings for the month of July 2018.

Atezolizumab (Tecentriq) has been granted a breakthrough therapy designation by the FDA for use in combination with bevacizumab (Avastin) as a first-line treatment for patients with advanced or metastatic hepatocellular carcinoma.

<em>Targeted Oncology</em>, a print and digital resource that offers content and expert opinions on precision medicine in oncology, becomes partners with the International Liver Cancer Association, announced Michael J. Hennessy Jr., president of MJH Associates Inc., parent company of <em>Targeted Oncology.</em>

Richard Kim, MD, recently shared his treatment considerations and decisions he makes when treating patients with hepatocellular carcinoma and colorectal cancer. Kim explained his treatment decisions based on 2 gastrointestinal case scenarios during a <em>Targeted Oncology</em> live case-based peer perspectives program.

The PD-1 inhibitor pembrolizumab (Keytruda) has been granted a priority review designation by the FDA for use in previously treated patients with advanced hepatocellular carcinoma,&nbsp;according to Merck, the manufacturer of the agent.

General Cancer

Bert H. O&rsquo;Neil, MD, recently shared his considerations for treatment when treating patients with gastrointestinal cancers. O&rsquo;Neil reviewed how he would treat patients with colon cancer and patients with hepatocellular carcinoma based on case scenarios during a <em>Targeted Oncology</em> live case-based peer perspectives presentation.<br /> &nbsp;